Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Sort By: Relevance
Journal Article
|Editorial
2025-03-01 • IJTLD OPEN
2025-03-01 • IJTLD OPEN
Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve...
Journal Article
|Research
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health
BACKGROUND
There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...
Journal Article
|Letter
2023-04-01 • International Journal of Tuberculosis and Lung Disease
2023-04-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|Research
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Journal Article
|Research
2020-02-01 • International Journal of Infectious Diseases
2020-02-01 • International Journal of Infectious Diseases
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at provid...
Journal Article
|Research
2020-03-17 • Lancet Respiratory Medicine
2020-03-17 • Lancet Respiratory Medicine
BACKGROUND
Tre...
Journal Article
|Research
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTING
Drug-resistant tuberculosis (TB) is an important public health problem in Latvia.
OBJECTIVE
To document trends, characteristics and treatment outcomes of registe...
Drug-resistant tuberculosis (TB) is an important public health problem in Latvia.
OBJECTIVE
To document trends, characteristics and treatment outcomes of registe...